Hetero Labs Limited Ledipasvir Export Data — India (DGFT 2022–2026)

Name: Hetero Labs Limited Ledipasvir Export Records India — #1 Exporter, 15 Shipments, $659.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Ledipasvir

India Pharmaceutical Trade Intelligence

$1.1M60 Suppliers44 CountriesHS 30049099

ExportsIndia → KYRGYZSTAN20.1%India → UZBEKISTAN18.7%

#1 Supplier: HETERO LABS

Hetero Labs Limited — Ledipasvir Exporter #1 | $659.7K Trade Value | TransData Nexus | TransData Nexus

Hetero Labs Limited — Ledipasvir Exporter Profile

Indian Pharmaceutical Exporter · #1 for Ledipasvir · $659.7K export value · DGFT Verified

Hetero Labs Limited is the #1 Indian exporter of Ledipasvir with $659.7K in export value and 15 verified shipments. Hetero Labs Limited holds a 58.1% market share in Ledipasvir exports across 5 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.

Hetero Labs Limited — Ledipasvir Export Profile: Buyers & Destinations

Hetero Labs Limited Ledipasvir export treemap — buyers and destination countries | TransData Nexus

Where Does Hetero Labs Limited Export Ledipasvir?

Country	Value	Shipments	Share
UZBEKISTAN	$200.0K	4	34.9%
KYRGHYSTAN	$100.0K	2	17.5%
KAZAKISTAN	$88.8K	2	15.5%
AZARBAIJAN	$80.0K	2	14.0%
KYRGYZSTAN

Who Are the Top Buyers of Ledipasvir from Hetero Labs Limited?

Buyer	Country	Value	Orders
TO THE ORDER OF	KAZAKISTAN	$402.5K	9
TO THE ORDER OF,	KYRGHYSTAN	$50.0K	1
M/S........	KYRGHYSTAN	$50.0K	1
TO THE ORDER OF	KAZAKHSTAN	$20.4K	1
TO THE ORDER	MALTA	$36	2

Hetero Labs Limited supplies Ledipasvir to 5 buyers globally. The largest buyer is TO THE ORDER OF (KAZAKISTAN), followed by TO THE ORDER OF, (KYRGHYSTAN) and M/S........ (KYRGHYSTAN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Ledipasvir Formulations Does Hetero Labs Limited Export?

Product Description / Formulation	Value	Shipments
LISOF, LEDIPASVIR 90MG + SOFOSBUVIR 400M	$280.0K	6
LISOF LEDIPASVIR 90MG + SOFOSBUVIR 400MG	$150.0K	3
LISOF (LEDIPASVIR 90MG + SOFOSBUVIR 400M	$50.0K	1
LISOF LEDIPASVIR+SOFOSBUVIR TABLET 28S (QTY: 390 CON) (PACK OF 28'S)TBS	$38.8K	1
LISOF (LEDIPASVIR+SOFOSBUVIR TABLET 28S)(23,856 TABLET)	$33.7K	1
LISOF LEDIPASVIR+SOFOSBUVIR TABLET (QTY:300 CON) (PACK OF 28'S)	$20.4K	1
LEDIFOS 1X28S LEDIPASVIR + SOFOSBUVIR TABS QTY: 43 PACK	$24	1
LEDIFOS 1X28S LEDIPASVIR + SOFOSBUVIRTABS QTY: 29 PACK	$12	1

Hetero Labs Limited exports 8 distinct Ledipasvir formulations including tablets, capsules, syrups, and combination drugs. The top formulation is LISOF, LEDIPASVIR 90MG + SOFOSBUVIR 400M with 6 shipments worth $280.0K.

How Does Hetero Labs Limited Compare to Nearest Ledipasvir Exporters?

Exporters ranked immediately above and below #1 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
1	HETERO LABS LIMITED ★	$659.7K	15	5	$44.0K
2	MYLAN LABORATORIES LIMITED	$229.2K	5	3	$45.8K
3	ROYAL MEDICAL PRIVATE LIMITED	$29.0K	9	1	$3.2K

Hetero Labs Limited ranks #1 among 60 Indian Ledipasvir exporters. Average shipment value of $44.0K compared to the market average of $17.8K. The closest competitors by value are MYLAN LABORATORIES LIMITED and ROYAL MEDICAL PRIVATE LIMITED.

Which Indian Ports Ship Ledipasvir Exports?

Port	Shipments	% Share
SAHAR AIR CARGO ACC (INBOM4)	75	32.9%
SAHAR AIR	40	17.5%
DELHI AIR CARGO ACC (INDEL4)	33	14.5%
DELHI AIR	19	8.3%
AHEMDABAD AIR	15	6.6%
Bombay Air	13	5.7%
AHEMDABAD AIR ACC (INAMD4)	9	3.9%
Delhi Air	4	1.8%

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Ledipasvir Exports

The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.

The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.

Hetero Labs Limited — Regulatory Compliance & Quality Standards

Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Ledipasvir shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 15 individual customs records matching Hetero Labs Limited exporting Ledipasvir, covering 8 formulations to 8 countries via 5 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 44+ countries, 90+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Ledipasvir

Ledipasvir

Hetero Labs Limited — Ledipasvir Exporter Profile

Hetero Labs Limited — Ledipasvir Export Profile: Buyers & Destinations

Where Does Hetero Labs Limited Export Ledipasvir?

Who Are the Top Buyers of Ledipasvir from Hetero Labs Limited?

What Is India's Total Ledipasvir Export Value and How Much Does Hetero Labs Limited Contribute?

What Is the Average Shipment Value for Hetero Labs Limited's Ledipasvir Exports?

How Does Hetero Labs Limited Compare to Other Indian Ledipasvir Exporters?

What Ledipasvir Formulations Does Hetero Labs Limited Export?

How Does Hetero Labs Limited Compare to Nearest Ledipasvir Exporters?

Which Indian Ports Ship Ledipasvir Exports?

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Ledipasvir Exports

Hetero Labs Limited — Regulatory Compliance & Quality Standards

About Hetero Labs Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Ledipasvir Export Data from Hetero Labs Limited

Ledipasvir Stats

Company Overview

Top Products by Hetero Labs Limited

Related Analysis

Need Detailed Export Data?

Data Source